Progress towards Elimination of HIV Mother-to-Child Transmission in the Dominican Republic from 1999 to 2011
Table 1
Characteristics of maternal HIV diagnosis, maternal and infant antiretroviral use, mode of delivery and infant feeding, Dominican Republic, 1999–2008, and 2009–2011.
Diagnosis and management
1999–2008
2009–2011
No. (%)
No. (%)
N = 1,274
N = 302
Time of HIV diagnosis
Before pregnancy
277 (21.7)
77 (25.5)
During pregnancy
617 (48.4)
143 (47.4)
Labor/delivery
73 (5.7)
38 (12.6)*
≤72 hours post-partum
66 (5.2)
5 (1.7)*
After 72 hours
160 (12.6)
38 (12.6)
Unknown
81 (6.3)
1 (0.3)*
Maternal antiretroviral use
Any
868 (68.1)
265 (87.7)*
HAART, either
157 (12.3)
205 (67.9)*
AZT + 3TC + NVP1
157 (12.3)
59 (19.5)
AZT-3TC-Lop2
—
146 (48.3)*
Multidose AZT
19 (1.5)
0
Multidose AZT + 3TC
61 (4.8)
—
Single dose NVP3
503 (39.5)
60 (19.5)*
Received no ARVs
406 (31.9)
37 (12.2)*
Unknown
121 (9.5)
0*
Type of delivery
Vaginal
285 (22.4)
81 (26.8)
All Caesareans
882 (69.2)
199 (65.9)
Elective caesarian
882 (69.2)
152 (50.3)
Emergency caesarean
—
47 (15.6)
Unknown
107 (8.4)
22 (7.3)
Infant nutrition
Formula only
972 (76.3)
260 (86.1)*
Breast feeding only
67 (5.3)
4 (1.3)*
Both
43 (3.4)
13 (4.2)
Unknown
192 (15.1)
25 (8.3)*
Infant antiretrovirals (ARVs)
Started between 8–72 hours
782 (61.4)
184 (60.9)
Multidose AZT
81 (6.4)
126 (41.7)*
Single-dose NVP only
701 (55.0)
58 (19.3)*
Did not receive ARVs
219 (17.2)
74 (24.6)*
Unknown
273 (21.4)
44 (14.5)*
*
P < .01 by time period.
1Zidovudine, lamivudine, nevirapine highly active antiretroviral therapy.
2Zidovudine, lamivudine, ritonavir-boosted lopinavir highly active antiretroviral therapy.
